drugset / Trial / NCT05826015
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase 1
Withdrawn
Washington University School of Medicine
Aravive, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine safety and tolerability of AVB-500 when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer.
Timeline
- Start
- 2024-10-31
- Primary completion
- 2029-06-03
- Completion
- 2034-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Batiraxcept | Protein / enzyme biologic | — | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |